@pubmed.ncbi.nlm.nih.gov.rss-feed.feed.id.1za4h3qg-nd.lvx8qfap6dogsjorqfx5gx1cfzpjgvflxsasr2.ff.20240827193420.utm.medium.rss.utm.content.1za4h3qg-nd.lvx8qfap6dogsjorqfx5gx1cfzpjgvflxsasr2.utm.source.rss-parrot-bot.v.2.18.0.post9.e462414@rss-parrot.net
I'm an automated parrot! I relay a website's RSS feed to the Fediverse. Every time a new post appears in the feed, I toot about it. Follow me to get all new posts in your Mastodon timeline! Brought to you by the RSS Parrot.
---
((Triple Negative Breast Neoplasmspathology[MAJR])): Latest results from PubMed
Feed URL: pubmed.ncbi.nlm.nih.gov/rss/search/1zA4h3Qg-ND_Lvx8qFap6dOGSjORqFX5gx1cFZpJGVFLXsasr2/
Posts: 8
Followers: 2
Survival outcomes of axillary de-escalation following neoadjuvant chemo-immunotherapy in clinically node-positive triple-negative breast cancer: a national cancer database study
Published: July 23, 2026 10:00
CONCLUSIONS: The enhanced systemic control conferred by ICIs appears to compensate for the reduced surgical clearance of the axilla when ALND is omitted, effectively mitigating the survival risks associated with omitting ALND in cN+ TNBC. These real-world…
TOMM40/FADS2 Expression Ratio Predicts the Sensitivity to mTOR Inhibitors in Triple-Negative Breast Cancer
Published: July 18, 2026 10:00
CONCLUSION: Our results provide a new therapeutic strategy using the TOMM40/FADS2 expression ratio to predict the cellular sensitivity to mTOR inhibitor treatment in TNBC.
Hypoxia-induced mechanism of TNBC promoting tumour cell proliferation through exosomal miRNA
Published: July 18, 2026 10:00
Triple-negative breast cancer (TNBC), characterized by the absence of ER, PR, and HER2 expression, is associated with aggressive clinical behavior and limited treatment options. Hypoxia in the tumor microenvironment (TME) may influence intercellular…
Impact of Neoadjuvant Immunochemotherapy on Surgical Outcomes in Management of Early Triple-Negative Breast Cancer
Published: July 17, 2026 10:00
CONCLUSION: NAIC did not significantly increase postoperative complications compared to NAC. However, irAEs and potential treatment delays warrant careful management. Despite these risks, NAIC remains a viable option for early TNBC with manageable surgical…
Epithelial-mesenchymal transition is associated with altered immune composition and cytotoxic function in triple-negative breast cancer
Published: July 17, 2026 10:00
CONCLUSIONS: These findings reveal that EMT is associated with immune cell recruitment and function in a graded manner, providing a rationale for integrating EMT phenotyping into therapeutic strategies to overcome immune resistance in breast cancer.
Sustained clinical benefit with sacituzumab govitecan in metastatic triple-negative breast cancer with extensive cutaneous involvement.
Published: July 16, 2026 10:00
Metastatic triple-negative breast cancer (mTNBC) remains a highly aggressive disease with limited therapeutic options after progression to standard treatments. Together with cutaneous metastases they represent an unmet need in the clinical history of…
Efficacy of sacituzumab govitecan in multi-treated metastatic breast cancer and clinical management of oligoprogressions.
Published: July 16, 2026 10:00
The case described concerns a 54-year-old woman diagnosed with triple-negative breast cancer, which initially presented with metastatic disease in the breast, axillary lymph nodes, skin, and liver. The diagnostic and therapeutic process lasted over eight…
Long-term treatment with sacituzumab govitecan in a patient with brain metastases from triple-negative breast cancer, PD-L1-negative, BRCA1/2 wild-type.
Published: July 16, 2026 10:00
We report the clinical case of a 64-year-old female patient who underwent a mastectomy with sentinel lymph node biopsy followed by adjuvant chemotherapy with anthracyclines and taxanes for triple-negative, BRCA wild-type invasive ductal carcinoma.…